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Abstract
An intact and fully functional innate immune system is criti-
cal in the defense against pathogens. Indeed, during sys-
temic infection, the ability of the organism to cope with the 
increased demand for phagocytes depends heavily on suf-
ficient replenishment of mature myeloid cells. This process, 
designated emergency or demand-adapted myelopoiesis, 
requires the activation of hematopoietic progenitors in the 
bone marrow (BM), resulting in their proliferation and differ-
entiation toward the myeloid lineage. Failure of BM progen-
itors to adapt to the enhanced need for mature cells in the 
periphery can be life-threatening, as indicated by the detri-
mental effect of chemotherapy-induced myelosuppression 
on the outcome of systemic infection. Recent advances dem-
onstrate an important role of not only committed myeloid 
progenitors but also of hematopoietic stem cells (HSCs) in 
emergency myelopoiesis. In this regard, pathogen-derived 
products (e.g., Toll-like receptor ligands) activate HSC differ-
entiation towards the myeloid lineage, either directly or in-
directly, by inducing the production of inflammatory media-
tors (e.g., cytokines and growth factors) by hematopoietic 
and nonhematopoietic cell populations. The inflammatory 
mediators driving demand-adapted myelopoiesis target not 
only HSCs but also HSC-supportive cell populations, collec-
tively known as the HSC niche, the microenvironment where 
HSCs reside. In this review, we discuss recent findings that 
have further elucidated the mechanisms that drive emer-
gency myelopoiesis, focusing on the interactions of HSCs 
with their BM microenvironment. © 2018 S. Karger AG, Basel
Introduction
The innate immune system is the first line of host de-
fense against pathogens. Several cell populations and sol-
uble factors act in concert to restrict pathogens and pre-
vent systemic infection. Innate immune cell mobilization 
from the bone marrow (BM), especially the mobilization 
of neutrophils, and their accumulation at the site of infec-
tion are crucial in containing the pathogen [1]. In the 
course of severe systemic infection, the acute demand for 
vast numbers of neutrophils to cope with the infection 
renders the constant replenishment of circulating neutro-
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phils from the BM imperative. This process, termed 
emergency or demand-adapted myelopoiesis, is mediat-
ed by the activation of hematopoietic stem cells (HSCs) 
and progenitor cells in the BM [2]. In this review, we dis-
cuss the contribution of hematopoietic progenitor cell 
populations to the innate immune response.
HSCs and Hematopoietic Hierarchy
HSCs, at the top of the hematopoietic hierarchy, are 
quiescent cells with multipotent and extensive self-re-
newal potential, and reside in the BM niche [3]. HSC 
maintenance in the BM niche and their activation status 
is regulated by cell-intrinsic factors including transcrip-
tionally regulated programs and cellular metabolism, as 
well as by the components of the niche micro-environ-
ment [4].
HSC differentiation to multipotent progenitor (MPP) 
cells is the initial step in a cascade of events resulting in 
mature hematopoietic cells, including cells of innate im-
munity, although tissue-resident macrophages may de-
rive from embryonic progenitors [5, 6]. MPPs show 
higher proliferation rates than HSCs, and are therefore 
considered to play a major role in the maintenance of un-
perturbed hematopoiesis, but the exact contribution of 
HSCs to steady-state hematopoiesis is under debate [7–
9]. MPPs subsequently give rise to progenitor cells with 
myeloid lineage commitment (common myeloid progen-
itors; CMPs) or lymphoid lineage commitment (common 
lymphoid progenitors; CLPs) [3]. There is an imbalance 
between the myeloid and lymphoid output of MPPs, since 
differentiation to CMPs has been shown to be substan-
tially higher than differentiation to CLPs [7]. Further 
steps of differentiation of CMPs toward more restricted 
progenitors, e.g., granulocyte-macrophage progenitors 
(GMPs), erythrocyte-megakaryocyte progenitors, and 
monocyte-dendritic cell progenitors, and, as a next stage, 
toward restricted granulocyte progenitors, monocyte 
progenitors, and common dendritic progenitors, result in 
a huge amplification of innate immune cell production, 
generating an adequate number of neutrophil cells [10, 
11]. 
The hierarchical model of hematopoiesis is, however, 
oversimplified, given the high heterogeneity of hemato-
poietic and myeloid progenitor cell populations [12, 13]. 
A typical example is the characterization of an HSC sub-
population that expresses CD41, which shows lineage 
bias toward myelopoiesis [14]. Similarly, MPPs can be di-
vided into subpopulations with increased myeloid or 
lymphoid bias based on the expression of the receptor 
tyrosine kinase Flt3 [15, 16]. Recent studies, using single-
cell analysis approaches and genetic labeling, have further 
demonstrated high heterogeneity in progenitor cell pop-
ulations, and, importantly, that lineage commitment de-
cisions may be taken earlier, at the level of primitive HSCs 
[17–19]. For example, it has been recently shown that at 
steady-state hematopoiesis, megakaryocyte-erythroid 
lineage derives from early HSCs, while certain HSC clones 
display a restricted output of myeloid lineage cells [17]. 
Single-cell transcriptomic analysis revealed a correlation 
between the myelopoiesis-related gene signature and sig-
natures associated with cell cycle and proliferation, fur-
ther underlining the increased necessity for myeloid cell 
production in the BM when compared to lymphocytes 
[19]. These findings challenge the long-standing percep-
tion that lineage specification takes place at the level of 
the bifurcation into CMPs and CLPs.
Emergency Myelopoiesis 
The production of innate immune cells, especially 
neutrophils, is a major task that the hematopoietic sys-
tem needs to fulfill under steady-state conditions, as the 
estimated daily production of neutrophils in adult hu-
mans is 0.5–1 × 1011 [20]. The demand for neutrophil 
generation increases dramatically during hematopoietic 
stress induced by chemotherapy-associated myeloabla-
tion or systemic infection/inflammation. Administra-
tion of myeloablative regimens often results in profound 
neutropenia, which can lead to life-threatening infec-
tious complications (febrile neutropenia) [21]. Systemic 
infection or inflammation is characterized by increased 
neutrophil numbers (neutrophilia) and the presence of 
myeloid precursor cells (“left shift”) in peripheral blood. 
This enhanced demand for the generation and release of 
neutrophils from the BM to peripheral blood upon sys-
temic infection/inflammation derives from the accumu-
lation of vast numbers of neutrophils and subsequent 
neutrophil cell death at the sites of pathogen invasion or 
inflammation [22].
Replenishment of the neutrophil pool after myeloabla-
tion or systemic infection requires the activation of dor-
mant HSCs, and a switch from a quiescent to a prolifera-
tive state [4]. In this context, several cytokines, growth 
factors, and pathogen-derived products, e.g., Toll-like re-
ceptor (TLR) ligands, including bacterial lipopolysaccha-
ride (LPS) or lipoproteins, may activate HSCs, thereby 
changing their transcriptional program [4]. This activa-
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tion of hematopoietic progenitors leads to an increased 
production of GMPs, which then expand in numbers, 
form clusters, and further differentiate towards neutro-
phils [23], facilitating emergency myelopoiesis. In the 
same context, a recent study demonstrated that commit-
ted neutrophil precursors proliferate and expand upon 
systemic infection or tumoral stress, giving rise to imma-
ture neutrophils that migrate to peripheral tissues [24].
Myeloid Growth Factors and Cytokines
Systemic infection/inflammation leads to a strong in-
crease in the levels of growth factors that promote myelo-
poiesis [25, 26]. Granulocyte colony-stimulating factor 
(G-CSF) is critical for basal neutrophil production, as 
shown by the reduced numbers of circulating neutrophils 
in mice deficient in G-CSF (Csf3-/-) or its cognate receptor 
(Csf3r–/–) [27, 28]. Moreover, G-CSF-deficient mice dis-
play decreased numbers of granulocyte precursors and 
defective neutrophil mobilization [27]. G-CSF acts di-
rectly on CMPs and GMPs, instructing them toward 
granulopoiesis [29, 30], but in the case of HSCs, it regu-
lates the cell cycle [31] and drives their mobilization in an 
indirect fashion, by affecting the BM microenvironment 
[32, 33]. During systemic inflammation, endothelial cells, 
rather than cells of hematopoietic origin like resident 
macrophages, are the main cellular source of G-CSF by 
responding to LPS through TLR4, as demonstrated by 
BM chimera experiments [34, 35]. In murine models of 
infection with different microbes, alongside G-CSF, gran-
ulocyte-macrophage (GM)-CSF has been implicated in 
emergency myelopoiesis, and G-CSF- and GM-CSF-in-
dependent pathways of neutrophil generation in emer-
gency myelopoiesis have been described upon infection 
with Candida albicans [36, 37]. The ability of G-CSF to 
promote HSC proliferation and drive myelopoiesis is 
therapeutically important. Indeed, prophylactic adminis-
tration of G-CSF is currently recommended for patients 
at an increased risk of developing febrile neutropenia 
[38, 39].
Macrophage colony-stimulating factor (M-CSF) acts 
also directly on HSCs, driving them toward myelopoiesis 
[40, 41]. M-CSF has been shown to activate PU.1, a mas-
ter regulator of myelopoiesis, instructing myeloid lineage 
decision [40]. In addition, GM-CSF activates hematopoi-
etic progenitors toward myelopoiesis [42, 43]. Although 
GM-CSF deficiency does not alter hematopoietic progen-
itor cell numbers under steady state, GM-CSF contributes 
to emergency myelopoiesis in response to infection with 
Mycobacterium avium [36]. Blocking of GM-CSF was 
further shown to impair the expansion of hematopoietic 
progenitors in the context of β-glucan-induced trained 
immunity [44].
Several studies have focused on the role of cytokines 
produced during systemic inflammation [45] for the ac-
tivation of hematopoietic progenitor cells in emergency 
myelopoiesis. IL-1β directly activates hematopoietic pro-
genitor cells, inducing cell cycle and myeloid bias [44, 46, 
47]. Weisser et al. [46] demonstrated that HSCs from 
mice with X-linked chronic granulomatous disease had 
increased cell proliferation, which was associated with 
defective repopulation potential and faster functional de-
cline. Increased numbers of myeloid progenitors are also 
present in these mice, a finding indicative of myeloid-
biased hematopoiesis. Blocking of IL-1 with the IL-1 re-
ceptor antagonist, anakinra, partially reversed the chang-
es in hematopoietic progenitors, providing evidence that 
IL-1 participates in the detrimental effect of chronic in-
flammation on HSC function in this model.
IL-1 has been found to increase the proliferation and 
differentiation rate of HSCs in vitro, without having a 
similar effect on less primitive hematopoietic progenitors 
[47]. This effect was associated with induction in HSCs of 
the transcription factor PU.1 and the receptors of the 
myeloid-lineage growth factors GM-CSF (Csf2ra) and 
M-CSF (Csf1r), which are regulated by PU.1. The same 
study also demonstrated that chronic IL-1 administration 
impairs HSC self-renewal potential and drives myeloid 
differentiation, whereas acute IL-1 production in the BM 
supports reconstitution of myelopoiesis upon myelosup-
pression.
IL-6 contributes to the response of hematopoietic pro-
genitors to emergency myelopoiesis after myeloablation. 
IL-6-deficient mice show an attenuated hematopoietic 
response to myeloablation after cytotoxic treatment [48], 
whereas administering IL-6 promotes the recovery of he-
matopoiesis after irradiation [49]. IL-27, a member of the 
IL-6/IL-12 family of cytokines, acts on hematopoietic 
progenitors in vitro, instructing them towards the my-
eloid lineage. Overexpression of IL-27 in mice was shown 
to promote myelopoiesis and suppress lymphopoiesis 
[50]. The role of this cytokine during emergency myelo-
poiesis was further confirmed in a model of malaria infec-
tion. As assessed by BM chimeras, ablation of the IL-27 
receptor subunit WSX-1 in hematopoietic progenitors at-
tenuated their expansion and their differentiation toward 
myeloid lineage, with significant consequences for the 
degree of parasitemia [51]. 
Interferon (IFN)-γ, a type II IFN that plays a critical 
role in host defense against pathogens, may impair the 
self-renewal capacity of HSCs [52–55]. Chronic myco-
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bacterial infection promotes the differentiation of HSCs, 
leading to the attenuation of their repopulation capacity; 
this has been attributed to IFN-γ, as shown by studies us-
ing mice lacking the ligand-binding chain of the IFN-γ 
receptor (Ifngr1–/–) [55, 56]. The role of IFN-γ in the re-
sponse of HSCs to mycobacterial infection, as well as to 
myeloablation induced by chemotherapy, was further re-
inforced by a study that assessed the involvement of the 
interferon-inducible GTPase Lrg-47 (Irgm1) in HSCs. 
Irgm1–/– mice showed impaired expansion of hematopoi-
etic progenitors in response to myeloablation induced by 
5-fluorouracil and infection with M. avium [57]. 
Direct HSC Activation by Pathogen-Associated 
Molecules
Pathogen-associated molecular patterns (PAMPs) can 
directly activate HSCs through pattern recognition recep-
tors, especially TLRs. HSCs express several TLRs [58]. In 
vitro activation of murine HSCs with TLR4 or TLR2 li-
gands, LPS, or Pam3CSK4 lipopeptide, respectively, pro-
motes cell proliferation and differentiation into myeloid 
lineage in a myeloid differentiation primary response 88 
(MyD88)-dependent manner [58].
Several groups have further tested the in vivo effect of 
TLR activation in hematopoietic progenitors. High-dose 
LPS administration results in pancytopenia by inducing 
cell death in BM cells and HSC dysfunction [59], whereas 
chronic in vivo administration of low-dose LPS over a 
period of up to 6 weeks results in the deterioration of the 
self-renewal and repopulating capacity of HSCs [60]. A 
recent study further demonstrated that LPS induces rep-
lication stress in HSC and impairs their repopulation ca-
pacity, in a pathway that involves reactive oxygen species 
(ROS), p38 mitogen-activated protein kinase (MAPK) 
and TRIF, but not MyD88 [61]. Interestingly, β-glucan-
induced trained immunity may reverse the LPS-associat-
ed replication stress in HSCs, thereby pointing to a pro-
tective mechanism by which trained immunity may pro-
mote myelopoiesis [44]. Rodriguez et al. [62] have shown 
that severe sepsis, induced by Pseudomonas aeruginosa or 
the administration of its LPS, blocks HSC differentiation 
toward myeloid lineage, resulting in neutropenia. The 
same group further demonstrated in the same model that 
the TLR4-TRIF pathway impairs HSC and MPP function, 
whereas the TLR4-MyD88 pathway mainly affects my-
eloid lineage-committed cells [63]. Another study dem-
onstrated that circulating HSCs can be recruited to sites 
of infection, where they generate tissue-resident myeloid 
cells in response to TLR activation [64]. Taken together, 
PAMPs can directly act on HSCs and induce their prolif-
eration to myeloid lineage cells, a process that aims at 
promoting the replenishment of innate immune cells.
Regulation of Myelopoiesis by Transcription Factors
The differentiation of progenitors to mature granulo-
cytes is tightly regulated by transcription factors, includ-
ing PU.1, GF1, CCAAT-enhancer binding protein-α (C/
EBPα), and C/EBPε [22]. PU.1 is critical for the differen-
tiation of HSCs toward the myeloid lineage in response to 
M-CSF [40] or IL-1β [47]. C/EBPα is also important for 
the progression of granulopoiesis, mainly by regulating 
the expression of the G-CSF receptor [22]. A recent study 
has further evaluated the expression and role of these 
transcription factors during the late stages of granulopoi-
esis [24]. Cebpa expression was increased in GMPs com-
pared to neutrophil precursors as well as immature and 
mature neutrophils, whereas Cebpe was necessary for the 
development of neutrophil precursors and was highly ex-
pressed in this cell population [24]. In addition, it was 
shown that mature neutrophils express higher levels of 
Cebpd than their precursors [24].
The HSC Niche in Emergency Myelopoiesis
Several nonhematopoietic and hematopoietic cell 
populations form a specialized microenvironment re-
quired for the maintenance of HSCs, designated the HSC 
niche [65]. Imaging of the BM reveals the perivascular 
localization of HSCs, even though the reports regarding 
their distribution in the perisinusoidal or periarteriolar 
region are conflicting [66, 67]. Perivascular mesenchymal 
stromal cells (MSCs) are critical players in the formation 
of the niche, by producing factors that support HSC 
maintenance [65]. In addition, sympathetic nerves, non-
myelinating Schwann cells, megakaryocytes, macro-
phages, and osteoclasts contribute to HSC niche for-
mation [65, 68]. On the other hand, osteolineage cells 
support the reconstitution of hematopoiesis after HSC 
transplantation into irradiated recipient mice [65].
These cell populations regulate HSC function via cell-
adhesive interactions and the release of soluble factors, 
like C-X-C motif chemokine ligand (CXCL)12, trans-
forming growth factor (TGF)β1 or stem cell factor [69]. 
CXCL12 is produced in the BM microenvironment by 
several cell populations, including perivascular MSCs, 
and especially CXCL12-abundant reticular (CAR) cells 
[70], endothelial cells [71], and osteoblasts, although the 
contribution of CXCL12 produced by osteoblasts in the 
regulation of HSCs is controversial [69, 70]. In a similar 
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fashion, stem cell factor, released by MSCs and endothe-
lial cells [72], and thrombopoietin [73] support HSC 
maintenance. Inflammatory stimuli suppress the expres-
sion of these retention molecules in the HSC niche, driv-
ing the activation and differentiation of HSCs [74]. For 
example, G-CSF downregulates CXCL12 expression in 
the BM, thereby inhibiting HSC retention [75].
Recent studies demonstrated that megakaryocytes 
play an important role in the maintenance of HSCs in the 
quiescent state, via the release of CXCL4 and TGFβ1 [68, 
76]. Moreover, megakaryocytes promote HSC prolifera-
tion by producing fibroblast growth factor (FGF)-1 in 
response to chemotherapy-induced myeloablation [76]. 
Resident macrophages play an important role in the BM 
microenvironment by regulating HSC niche via the clear-
ance of aged neutrophils [77].
Besides releasing important soluble factors, endothe-
lial cells regulate HSC trafficking, which takes place spe-
cifically at sinusoids due to increased vascular permeabil-
ity. The increased permeability in sinusoids, compared to 
arterioles, was further associated with significantly in-
creased levels of intracellular ROS in HSCs residing at the 
perisinusoidal region [71]. Since ROS promote the differ-
entiation of HSCs [78], this finding suggests that the de-
creased permeability of arterioles may contribute to the 
increased quiescence of HSCs residing in the periarterio-
lar area. Consistently, endothelial cell-specific deletion of 
FGF receptor (Fgfr)-1 and -2 results in the disruption of 
vascular integrity, leading to increased levels of ROS in 
HSCs and a bias toward myeloid lineage after transplan-
tation [71].
Cell-to-cell and cell-to-extracellular matrix interac-
tions regulate HSC trafficking, retention, and quiescence 
in the BM microenvironment. E-selectin expressed in BM 
endothelial cells drives the proliferation of HSCs, affect-
ing their response to chemotherapy [79]. Integrins ex-
pressed in HSCs play a major role in the adhesive interac-
tion between HSCs and cells that form the HSC niche. For 
example, α4β1 integrin on HSCs contributes critically to 
the engraftment and mobilization of HSCs [80, 81]. Integ-
rins of the β3 family also influence HSC function. For in-
stance, intracellular signaling downstream of β3 integrin 
ligation regulates the effect of other factors like thrombo-
poietin and IFN-γ [54, 82]. In the same context, we have 
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Fig. 1. Regulation of myelopoiesis in the hematopoietic stem cell 
(HSC) niche. a HSCs remain quiescent and are responsible for the 
maintenance of hematopoiesis. b Myeloablation or systemic in-
flammation drives HSC activation and differentiation to myeloid 
progenitors, to restore myelopoiesis. This balance between steady 
state and activation of HSCs depends on interactions with HSC 
niche, formed by mesenchymal stem cells (MSCs), endothelial 
cells, megakaryocytes, and macrophages. Factors that mediate 
HSC maintenance or proliferation/differentiation are listed. 
CXCL, C-X-C motif chemokine ligand; SCF, stem cell factor; TPO, 
thrombopoietin; TGF, transforming growth factor; IL, interleukin; 
TLR, Toll-like receptor; IFN, interferon; M-CSF, macrophage col-
ony-stimulating factor; G-CSF, granulocyte-colony stimulating 
factor; GM-CSF, granulocyte-macrophage colony-stimulating 
factor; Del-1, developmental endothelial locus-1; OPN, osteopon-
tin; MyP, myeloid progenitor.
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recently shown that developmental endothelial locus 
(Del)-1, a protein produced in the BM by CAR cells and 
the endothelium, regulates HSC function by acting as a 
ligand of β3 integrin [83]. Del-1 deficiency impairs the 
regeneration of myelopoiesis after transplantation or 
LPS-induced systemic inflammation [83]. Additionally, 
competitive repopulation assays using donor cells from 
mice deficient in Del-1 [83] or mice with Del-1 over-
expression in the endothelium [84], revealed a role for 
Del-1 in priming HSCs toward a myeloid lineage. An-
other protein expressed by BM stroma cells is osteopon-
tin (OPN), which also regulates HSC function, albeit 
through α9β1 integrin [85, 86]. Decreased levels of OPN 
in aged BM have been recently associated with the my-
eloid skewing typically observed in aging [85], while OPN 
suppresses myelopoiesis in favor of lymphopoiesis during 
systemic fungal infection [87]. Distinct OPN isoforms 
may exert different actions; whereas the intracellular iso-
form is responsible for the impaired expansion of my-
eloid progenitors, the secreted isoform drives the expan-
sion of CLPs [87]. Therefore, the interplay between HSCs, 
cell populations forming the niche, and locally produced 
soluble factors regulates the balance between HSC quies-
cence (Fig.  1a) and differentiation-associated prolifera-
tion (Fig. 1b). 
Conclusion
Hematopoietic progenitors are a critical component of 
innate immunity, enabling the replenishment of innate 
immune populations in emergency myelopoiesis in the 
context of systemic infection or after chemotherapy-in-
duced myelosuppression. Emergency myelopoiesis is a 
tightly regulated process involving contributions by sev-
eral inflammatory mediators and HSC niche factors that 
typically tilt the hematopoiesis balance toward a myeloid 
lineage. The recently revealed molecular mechanisms 
provide promising molecular targets for the optimization 
of myelopoiesis in the context of disorders such as febrile 
neutropenia associated with chemotherapy.
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